President Trump said he will sign an executive order on Monday, and if implemented, he said he could let it go The cost of certain drugs. This is a revival attempt The program he tried and failed Implemented during his first term.

Mr. Trump promises to guide the U.S. Department Health and Public Services Use Medicare to pay for medications in a doctor's office with the lowest price paid in other countries.

The president posted on his social media website on Sunday, pledging to sign the order at the White House on Monday morning.

"Our country will eventually be treated fairly, and our citizens' health care costs will be reduced by numbers that have never been thought of before," Trump added.

The president mocked the Oval Office's "very important announcement" last week, confirming Friday to CBS News that it would be the so-called "most popular country" program to lower Medicare drug prices.

Mr. Trump's Secretary of Health and Human Services Robert F. Kennedy Jr.

"Now, the biggest hurdle is actually price," Kennedy said in an interview with Newsmax. "And we are negotiating with pharmaceutical companies to see if we can at least start some pilot programs, or if we can get a low enough price we can offer it to everyone at government costs."

"If we do this for Medicaid, Medicare pays for it, and private insurers have to pay for it, we will increase health insurance costs to most employers in this country. It's really disruptive," Kennedy said.

The proposal may only affect certain medications covered by Medicare and are given in the office – considering infusions and other injections for treating cancer. But while experts believe that the “trillions of dollars” that Mr. Trump boasted in his post may be exaggerated, it could bring considerable savings to the administration.

Medicare provides health insurance to approximately 70 million older Americans. Complaints about U.S. drug prices, even when compared to other large and wealthy countries, have long attracted the anger of lawmakers on both sides, but the lasting solution never cleared Congress.

Under the plan's order, the federal government will link the pharmaceutical companies it pays for these drugs to the prices paid by other economically developed countries.

The proposal could face fierce opposition from the pharmaceutical industry.

This is the rule that Mr. Trump tried to pass in his first term, but it will never pass. He signed a similar executive order in his final weeks as president, but later a court order prevented the rule from taking effect on procedural issues during rulemaking, which later refused to pursue after the Biden administration.

The pharmaceutical industry believes that Mr. Trump's 2020 attempt will put foreign governments "above" in determining the value of U.S. drugs. The industry has long believed that forcing lower prices will hurt profits and ultimately affect innovation and its efforts to develop new drugs.

The court order sought by the pharmaceutical industry and others prevented the Centers for Medicare and Medicaid Services or CMS from implementing the proposal during Mr. Trump’s first term, saying the administration failed to develop and implement the policy through appropriate rule-making steps.

The Biden administration abandoned the proposal in 2022, accusing the court orders of blocking patterns and concerns raised by stakeholders, including fears it would cut off some Medicare beneficiaries from drug and response providers.

The plan only has the medications for Part B of Medicare (insurance for doctors’ office visits) that may cover the plan. Medicare beneficiaries are responsible for charging some fees to obtain these drugs during a doctor's visit, and for traditional Medicare participants, there is no annual out-of-pocket fee for the fees they pay.

A report by the Trump administration during his first term found that the U.S. spends twice as much on reporting the drugs than other countries. Medicare Part B drug spending exceeded US$33 billion in 2021.

More common prescription medications filled in the pharmacy may not be covered by new orders.

Mr. Trump entered his first term, accusing pharmaceutical companies of “escaping murder” and complaining that other government-setting drug prices are taking advantage of American countries.

On Sunday, the president once again targeted the industry and wrote: “Pharma/pharmaceutical companies would say that for years it was R&D costs, all of which were, and, anyway, would be borne by the “sucker” of the United States alone.”

He refers to the strong lobbying efforts of pharmaceutical companies, and he said campaign donations “can do miracles but can’t be with the Republican Party.”

“We will do the right thing,” he wrote.